semaglutide
Pre-clinical- Indications
- Type 2 diabetes, Obesity
Company intelligence / Profile preview
Cyprumed
Innsbruck, Tyrol, Austriacyprumed.net ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Cyprumed has developed proprietary oral drug delivery technologies that enable the transformation of peptides and certain injectable drugs into orally bioavailable tablet formulations. The company’s technology has been validated through major partnerships with pharmaceutical companies such as Merck & Co. (MSD), Bayer, Boehringer Ingelheim, and Ferring. Recent deals include a $493 million license agreement with Merck to use Cyprumed’s platform for multiple peptide targets. No independent clinical results have been published by Cyprumed itself; its value is demonstrated through industry collaborations.
- Therapeutic areas
- Other
- Modalities
- Peptides (including GLP-1 analogues, macrocycles, mini-proteins)Biopharmaceutics Classification System injectable (BCS Class IV) drugs
- Industry
- Drug Discovery Services
02
Drug pipeline
1 asset03
Partnerships
Merck & Co., Inc. / MSD ($493M licensing deal for oral peptide delivery platform)BayerBoehringer IngelheimFerring
Beyond the preview
Go deeper on Cyprumed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyprumed.